ReviewJACC. CardioOncology2021
Venous and Arterial Thromboembolism in Patients With Cancer:
Review in JACC. CardioOncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Incidence of arterial and venous thromboembolism in cancer patients- insights from more than 5,000,000 patients.Journal of thrombosis and thrombolysis · 2025Pooled it
- Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism.Nature reviews. Cardiology · 2026Review
- Enhancing venous thromboembolism risk prediction after immunotherapy for lung cancer.iScience · 2026Article
- Review
- Perioperative and Long-Term Outcomes of Lower Extremity Revascularization in Patients With Malignancy.Vascular and endovascular surgery · 2026Article
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer.iScience · 2026Article
- Cancer-associated arterial thromboembolism: real-world burden from a nationwide electronic health record database.Journal of the National Cancer Institute · 2026Article
- Comparison of Direct Oral Anticoagulants and Low-Molecular-Weight Heparins in Cancer Patients with Nonvalvular Atrial Fibrillation: Insights from a Single-Center Experience.Anatolian journal of cardiology · 2026Article
- When Cancer Clots: An Extensive Radiologic Analysis of Cancer-Associated Thromboembolism.Cancers · 2026Review
- The coagulation-inflammation axis in advanced cancer: associations with cardiovascular-thrombotic complications.Journal of thrombosis and thrombolysis · 2026Article
- Sex disparities in the associations between accelerometer-measured movement behaviors and subsequent thromboembolism risk in cancer patients.Biology of sex differences · 2026Article
- Antithrombotic therapy for cancer-associated venous thromboembolism.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Review
- Understanding Cardio-Oncology: A Survey-Based Study Conducted by the Heart Failure Association of the Polish Cardiac Society and the Polish Society of Clinical Oncology.Journal of clinical medicine · 2026Article
- Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding.Journal of thrombosis and thrombolysis · 2026Review
- Chemotherapy-associated coronary thrombosis presenting as acute coronary syndrome in breast cancer: a case report.BMC cardiovascular disorders · 2026Article
- Predictors of One-Year Mortality in Hospitalized Patients with Splenic Infarction: Survival Analysis of a Retrospective Cohort in Taiwan.International journal of medical sciences · 2026Article
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- Clinical Characteristics and Prognosis of Thromboembolism in Elderly Patients With Stage IV Lung Cancer.Geriatrics & gerontology international · 2026Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, represents a major cause of morbidity and mortality in patients with cancer. Arterial thromboembolism, including myocardial infarction and stroke, is also prevalent. Risk differs in subgroups, with higher rates observed in specific cancers including pancreas, stomach, and multiple myeloma. Thromboprophylaxis is recommended for most patients with active cancer hospitalized for medical illnesses and after major cancer surgery. Outpatient thromboprophylaxis is not routinely recommended, but emerging data suggest that a high-risk population that benefits from pharmacological thromboprophylaxis can be identified using a validated risk tool. Direct oral anticoagulants are emerging as the preferred new option for the treatment of cancer-associated VTE, although low-molecular-weight heparin remains a standard for patients at high bleeding risk. Management of VTE beyond the first 6 months and challenging clinical situations including intracranial metastases and thrombocytopenia require careful management in balancing the benefits and risks of anticoagulation and remain major knowledge gaps in evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.